Fortress Biotech
FBIO
50 hedge funds and large institutions have $6.21M invested in Fortress Biotech in 2024 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 5 closing their positions.
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
40% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 10
37% more call options, than puts
Call options by funds: $93K | Put options by funds: $68K
25% more funds holding
Funds holding: 40 → 50 (+10)
11% more capital invested
Capital invested by funds: $5.61M → $6.21M (+$599K)
1.81% more ownership
Funds ownership: 15.95% → 17.76% (+1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$161K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$160K |
| 3 |
MWM
Meridian Wealth Management
Lexington,
Kentucky
|
+$119K |
| 4 |
Millennium Management
New York
|
+$118K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$115K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$227K |
| 2 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$43.3K |
| 3 |
VF
Virtu Financial
New York
|
-$31K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$26.4K |
| 5 |
Goldman Sachs
New York
|
-$23.8K |
FBIO Hedge Fund Activity: Q2 2024 in Review
50 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech (FBIO) for Q2 2024, worth a combined $6.21M — up 11% from $5.61M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new FBIO positions and 5 closed out — a net gain of 10 holders — while 14 added to existing stakes and 10 trimmed.
The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $161K. The largest seller was Nantahala Capital Management, cutting an estimated $227K.
- 50 institutional investors held Fortress Biotech (FBIO) as of Q2 2024, up from 40 in Q1 2024.
- Funds reported $6.21M of Fortress Biotech stock for Q2 2024, up 11% quarter-over-quarter.
- 15 funds opened new Fortress Biotech positions in Q2 2024 and 5 closed out, a net change of +10 holders.
- The largest Fortress Biotech buyer in Q2 2024 was Cambridge Investment Research Advisors, an estimated $161K added.
- The largest Fortress Biotech seller in Q2 2024 was Nantahala Capital Management, an estimated $227K sold.
Based on aggregated 13F filings for Q2 2024.